Ripple Locks 700 Million XRP Back in Escrow After October Release 
Citi Raises Bitcoin Target to $113,000 as Crypto Outlook Improves 
XRP Ledger Hits 10 Million AI Payments as Bitcoin Retreats 
Circle Urges EU to Revise MiCA Stablecoin Rules 
Evernorth Set for Nasdaq Debut With 473 Million XRP Treasury 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Zcash Awards $8 Million in Grants After Orchard Bug Crisis 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
WordPress Malware Uses Ethereum to Evade Removal 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Malaysia Aviation Group to Buy Airbus SAE Unit 
MSTR Stock Rises 3% as Strategy Challenges MSCI Bitcoin Stance 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Trump Praises Boeing 737 Max After Flydubai Crash Attempt 
Add as a preferred source on Google
SAN DIEGO, Feb. 21, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration and fibrotic diseases, announced today that it will report its fourth quarter and full year 2016 financial and operating results after the close of U.S. financial markets on Tuesday, February 28, 2017. In addition, management will host a conference call to provide an update on corporate activities and discuss the quarterly financial results.
| Conference call and webcast: | |
| Date: | February 28, 2017 |
| Time: | 4:30 pm Eastern Time (1:30 pm Pacific Time) |
| Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
| Passcode: | 73756754 |
| Via web: | www.traconpharma.com; “Events and Presentation” section within the “Investors” section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, ophthalmic and fibrotic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with Santen Pharmaceutical Company Ltd.; and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
Company Contact: Casey Logan Chief Business Officer (858) 550-0780 ext. 236 [email protected] Investor Contact: Andrew McDonald LifeSci Advisors LLC 646-597-6987 [email protected]
